Literature DB >> 1827237

Decrease in the AgNOR number in Dunning R3327 prostate cancers after treatment with an agonist and antagonist of luteinizing hormone-releasing hormone.

K Szepeshazi1, E Korkut, A V Schally.   

Abstract

The argyrophilic staining of the nucleolar organizer region (AgNOR) in cells of Dunning R3327 rat prostate tumors was studied and the effect of hormonal treatments on their appearance was analyzed. The nuclei of the control tumor cells contained 4.1 +/- 0.17 AgNOR granules. Treatment of rats for 8 weeks with luteinizing hormone-releasing hormone (LH-RH) agonist (D-Trp-6-LH-RH) and antagonist SB-75 induced a marked inhibition of tumor growth and decreased significantly (P less than 0.01) the number of Ag-NORs in the tumors to 2.89 +/- 0.10 AgNOR granules/cell in the group given the agonist and to 2.82 +/- 0.10 after therapy with the highest dose of the antagonist. A reduced AgNOR number (3.14 +/- 0.16) also was found after 3 days of treatment with SB-75 (P less than 0.05), but the AgNORs returned to near control values 1 week after the short-term therapy, showing the reversibility of these changes. These results suggest that the AgNOR method, which was widely tested on human tumors in the past few years, can be a valuable technique in experimental tumor pathology and useful in the evaluation of the effects of various treatments.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827237      PMCID: PMC1886018     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  18 in total

1.  Hormone-modulated rRNA gene activity is visualized by selective staining of the NOs.

Authors:  A de Capoa; A Baldini; P Marlekaj; C Natoli; M Rocchi; N Archidiacono; S Cianfarani; G L Spadoni; B Boscherini
Journal:  Cell Biol Int Rep       Date:  1985-09

2.  Do AgNOR counts reflect cellular ploidy or cellular proliferation? A study of trophoblastic tissue.

Authors:  U R Suresh; L Chawner; C H Buckley; H Fox
Journal:  J Pathol       Date:  1990-03       Impact factor: 7.996

3.  Improved silver technique for showing nucleolar organiser regions in paraffin wax sections.

Authors:  K Y Chiu; S L Loke; K K Wong
Journal:  J Clin Pathol       Date:  1989-09       Impact factor: 3.411

4.  The silver-stained proteins of interphasic nucleolar organizer regions as a parameter of cell duplication rate.

Authors:  D Trerè; A Pession; M Derenzini
Journal:  Exp Cell Res       Date:  1989-09       Impact factor: 3.905

5.  Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method.

Authors:  W M Howell; D A Black
Journal:  Experientia       Date:  1980-08-15

6.  AgNOR numbers in rat pituitary corticotrophs following adrenalectomy or corticotrophin releasing factor administration.

Authors:  S E Peebles; A M McNicol
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1989

7.  Chromosomal changes associated with progression of the Dunning R-3327 rat prostatic adenocarcinoma system.

Authors:  N Wake; J Isaacs; A A Sandberg
Journal:  Cancer Res       Date:  1982-10       Impact factor: 12.701

8.  Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

9.  Silver staining, immunofluorescence, and immunoelectron microscopic localization of nucleolar phosphoproteins B23 and C23.

Authors:  D L Spector; R L Ochs; H Busch
Journal:  Chromosoma       Date:  1984       Impact factor: 4.316

10.  Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  E Korkut; L Bokser; A M Comaru-Schally; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

View more
  7 in total

1.  Effect of a cytotoxic analog of LH-RH (T-98) on the growth of estrogen-dependent MXT mouse mammary cancers: correlations between growth characteristics and EGF receptor content of tumors.

Authors:  K Szepeshazi; A V Schally; G Halmos; B Szoke; K Groot; A Nagy
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Investigational Strategies for Detection and Intervention in Early-Stage Pancreatic Cancer. April 24-27, Annapolis, Maryland. Abstracts.

Authors: 
Journal:  Int J Pancreatol       Date:  1994 Oct-Dec

3.  Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.

Authors:  Ana M Bajo; Andrew V Schally; Magdalena Krupa; Francine Hebert; Kate Groot; Karoly Szepeshazi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

4.  Growth inhibition of estrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination.

Authors:  K Szepeshazi; S Milovanovic; K Lapis; K Groot; A V Schally
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

5.  Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  T Yano; J Pinski; G Halmos; K Szepeshazi; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

6.  Effective treatment of experimental U-87MG human glioblastoma in nude mice with a targeted cytotoxic bombesin analogue, AN-215.

Authors:  Z Szereday; A V Schally; A Nagy; A Plonowski; A M Bajo; G Halmos; K Szepeshazi; K Groot
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

7.  Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.

Authors:  K Szepeshazi; A V Schally; K Groot; P Armatis; G Halmos; F Herbert; B Szende; J L Varga; M Zarandi
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.